RhumbLine Advisers
ENFN

RhumbLine Advisers’s Enfusion, Inc. ENFN Stock Holding History

RhumbLine Advisers’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-66,335
Closed -$740K – 4304
2025
Q1 		$740K Buy
66,335
+3,871
+6% +$42.8K ﹤0.01% 2321
2024
Q4 		$643K Buy
62,464
+1,796
+3% +$17.4K ﹤0.01% 2503
2024
Q3 		$576K Buy
60,668
+1,233
+2% +$10.6K ﹤0.01% 2609
2024
Q2 		$506K Buy
59,435
+13,832
+30% +$127K ﹤0.01% 2670
2024
Q1 		$422K Sell
45,603
-184
-0.4% -$1.62K ﹤0.01% 2773
2023
Q4 		$444K Buy
45,787
+3,033
+7% +$28.3K ﹤0.01% 2733
2023
Q3 		$383K Buy
42,754
+7,747
+22% +$73.6K ﹤0.01% 2774
2023
Q2 		$393K Buy
35,007
+1,098
+3% +$9.73K ﹤0.01% 2845
2023
Q1 		$356K Buy
33,909
+1,600
+5% +$17.6K ﹤0.01% 2560
2022
Q4 		$312K Buy
32,309
+956
+3% +$10.8K ﹤0.01% 2666
2022
Q3 		$387K Buy
31,353
+2,220
+8% +$27.1K ﹤0.01% 2612
2022
Q2 		$297K Buy
29,133
+7,410
+34% +$81.9K ﹤0.01% 2760
2022
Q1 		$276K Buy
21,723
+5,468
+34% +$83.5K ﹤0.01% 2668
2021
Q4 		$340K Buy
+16,255
New +$328K ﹤0.01% 2669

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RhumbLine Advisers's ENFN Position: Q2 2025 in Review

RhumbLine Advisers sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 66,335 shares — an estimated $740K sold.

RhumbLine Advisers first reported a position in ENFN in Q4 2021 and held it in 14 quarters. The position peaked at $740K in Q1 2025. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • RhumbLine Advisers reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 66,335 Enfusion, Inc. shares in Q2 2025, an estimated $740K.
  • RhumbLine Advisers first reported a position in Enfusion, Inc. in Q4 2021 and held it in 14 quarters.
  • RhumbLine Advisers's Enfusion, Inc. position peaked at $740K in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.